SHELTON, Conn., Dec. 1, 2016 /PRNewswire/ -- NanoViricides, Inc.
(NYSE MKT: NNVC), a global leader in the development of highly
effective antiviral therapies based on a novel nanomedicines
platform (the "Company"), announced today that it has published a
letter from the Company's CEO addressing its shareholders on its
website (www.nanoviricides.com).
In this letter, Dr. Eugene
Seymour, CEO of the Company, surveys the Company's
accomplishments in the past fiscal year that ended June 2016, and more recent events. The letter
describes the progress that the Company has made towards entering
human clinical trials. The Company believes that a nanoviricideĀ®
skin cream against shingles will be its first drug to go into human
clinical studies. The Company expects that additional HerpeCiodeā¢
program topical drug candidates will follow the shingles drug
candidate into the clinic.
In addition, the letter lays out the steps that the Company will
be accomplishing in the near future as it advances the shingles
drug into human trials. Over one million cases of shingles are seen
in the US annually with 70% of these cases being found in elderly
and immunocompromised individuals.
The Company has four different drugs in development in the
HerpeCide program. All of these high priority drugs are topical
treatments, which is expected to enable a relatively rapid
regulatory process as compared to systemic drugs.
Further, the Company has four more systemically delivered drugs
in different preclinical development stages that are expected to
mature towards the clinic. The Company continues to work on these
drug candidates at lower priorities, due to resource
limitations.
The Company believes its future is very bright, with four
topical drug candidates and additional four systemic drug
candidates in development. These drugs taken together address over
$40Bn in market size in herpesviral
diseases (cold sores, genital ulcers, herpes keratitis, shingles,
and others), influenzas (broad spectrum injectable drug for
hospitalized patients with severe viral influenzas, oral
nanomedicine drug for out-patients with influenza), HIV, and dengue
viruses.
The Company believes it now has the infrastructure to develop
antiviral drugs from discovery all the way to clinical product
manufacture in its new campus in Shelton,
CT. This has strengthened the Company's position as it would
allow the Company to become a stand-alone antiviral pharmaceuticals
company. The Company believes it will pursue out-licensing or
co-development strategies with other partners where
possible.
The letter is available at
http://www.nanoviricides.com/2016-ceo-letter.pdf.
About NanoViricides:
NanoViricides, Inc. (www.nanoviricides.com) is a development stage
company that is creating special purpose nanomaterials for
antiviral therapy. The Company's novel nanoviricideĀ® class of drug
candidates are designed to specifically attack enveloped virus
particles and to dismantle them. The Company is developing drugs
against a number of viral diseases including VZV, oral and genital
Herpes, viral diseases of the eye including EKC and herpes
keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV,
Hepatitis C, Rabies, Dengue fever, and Ebola virus, among
others.
This press release contains forward-looking statements that
reflect the Company's current expectation regarding future events.
Actual events could differ materially and substantially from those
projected herein and depend on a number of factors. Certain
statements in this release, and other written or oral statements
made by NanoViricides, Inc. are "forward-looking statements" within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. You should not
place undue reliance on forward-looking statements since they
involve known and unknown risks, uncertainties and other factors
which are, in some cases, beyond the Company's control and which
could, and likely will, materially affect actual results, levels of
activity, performance or achievements. The Company assumes no
obligation to publicly update or revise these forward-looking
statements for any reason, or to update the reasons actual results
could differ materially from those anticipated in these
forward-looking statements, even if new information becomes
available in the future. Important factors that could cause actual
results to differ materially from the company's expectations
include, but are not limited to, those factors that are disclosed
under the heading "Risk Factors" and elsewhere in documents filed
by the company from time to time with the United States Securities
and Exchange Commission and other regulatory authorities.
Although it is not possible to predict or identify all such
factors, they may include the following: demonstration and proof of
principle in pre-clinical trials that a nanoviricide is safe and
effective; successful development of our product candidates; our
ability to seek and obtain regulatory approvals, including with
respect to the indications we are seeking; the successful
commercialization of our product candidates; and market acceptance
of our products.
Logo - http://photos.prnewswire.com/prnh/20150107/167444LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/nanoviricides-publishes-a-letter-from-the-ceo-to-shareholders-on-its-website-300371162.html
SOURCE NanoViricides, Inc.